Biote Corp. Class A Common Stock (BTMD) Stock Price
BTMDStock
$1.08−62.59%52W
Market Cap$36.78M
P/E1.44x
PEG Ratio—
Div yield—
Beta1.75
BTMD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-51.57%
Price vs S&P 500 (4W)-16.79%
VGM Score46.59
P/E Ratio (Annual)1.44x
BTMD Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.03 | $0.04 | +18.00%(+$0.01) | |
| Q1 2026 | $0.08 | $0.08 | -2.13%(-$0.00) | |
| Q4 2025 | $0.10 | $0.07 | -29.80%(-$0.03) | |
| Q3 2025 | $0.12 | $0.18 | +48.08%(+$0.06) | |
| Q2 2025 | $0.13 | $0.16 | +26.52%(+$0.03) |
BTMD Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.09
4.09
4.09
4.09
Industry Peers — Pharmaceutical Preparations(21)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
BTMDBiote Corp. Class A Common Stock | A | D | D | 0.2x | -7.8% | 68.6% | -26.8% | $1.08 |
| RGCRegencell Bioscience Holdings Limited Ordinary Shares | — | — | B | — | — | — | — | $9.59 |
| DFTXDefinium Therapeutics, Inc. Common Shares | — | — | B | — | — | — | — | $32.10 |
| TRLVTrulieve Cannabis Corp. | B | C | A | 1.7x | -3.9% | 59.5% | — | $10.01 |
| CRONCronos Group Inc. Common Share | C | B | A | 6.6x | 37.5% | 46.5% | -50.0% | $3.21 |
| TLRYTilray Brands, Inc. Common Stock | B | B | D | 0.5x | 15.9% | 29.1% | — | $3.04 |
| CGCCanopy Growth Corporation Common Shares | B | C | D | 1.6x | 6.8% | 28.5% | — | $0.71 |
| SNDLSundial Growers Inc. Common Shares | B | C | B | 0.5x | -1.7% | 26.2% | — | $1.25 |
| GLASGlass House Brands Inc. | B | C | D | 1.2x | -25.6% | 30.8% | — | $3.19 |
| USNAUSANA Health Sciences Inc | B | D | C | 0.3x | 5.7% | 77.5% | -37.0% | $15.54 |
| ACBAurora Cannabis Inc. Common Shares | B | D | B | 1.3x | -18.9% | 6.3% | — | $3.99 |
About Biote Corp. Class A Common Stock
Biote Corp provides hormone optimization solutions and operational support to licensed practitioners. The company supplies practitioners with products and tools to offer personalized hormone therapy programs to patients. Biote generates revenue through operations in the United States and international markets.